Innovacell's Business Model

Innovacell A.G. originated as a cell therapy startup that was spun out from the Medical University of Innsbruck in Austria in 2000. Innovacell Inc. was then established as the parent company of this Austrian entity in Japan in January 2021. Our current board members represent multiple nationalities, including Japan, Austria, and the United States, each with experience managing regenerative medicine companies worldwide. This global background naturally shapes our business operations, ensuring a global perspective in every phase—from sourcing and development to commercialization.

Our group brings deep expertise in regenerative medicine and cell therapy. Our executive team has decades of experience in regulatory affairs and global R&D within the regenerative medicine space. Through years of consulting and collaboration, they have developed a comprehensive understanding of the industry and built a broad network of relationships with executives from both domestic and international companies.
Our subsidiary, Innovacell GmbH, has been actively engaged in cell therapy research and development for more than 20 years. With its own GMP-certified manufacturing facilities and proprietary technologies, Innovacell not only develops its own products but also provides manufacturing technologies and contract manufacturing services to other companies for their R&D needs.

Leveraging this extensive knowledge and experience, we identify unmet medical needs and promising regenerative medicine and cell therapy candidates with strong commercialization potential. Through proprietary research and analysis, we continuously expand our development pipeline. Additionally, we assess regulatory frameworks across different countries and evaluate the maturity of business infrastructure required for product and formulation development—enabling us to efficiently advance each candidate toward global commercialization.
Currently, our group is focused on developing and commercializing three cell therapy pipelines targeting incontinence: urge fecal incontinence, stress fecal incontinence, and stress urinary incontinence.

Since the early 2000s, regenerative medicine and cell therapy products have been commercialized globally, accompanied by the parallel development of essential business infrastructure. One of the primary challenges faced by startups in this field is identifying which external infrastructures to adopt in order to bring their products to market efficiently and cost-effectively.

At Innovacell, we leverage our organization’s accumulated knowledge, experience, and network to strategically assemble the optimal mix of resources—skills, personnel, development support services, business partners, and funding—tailored to each pipeline’s development and commercialization needs, always with a global perspective. In essence, our group’s added value lies in our ability to design and implement the most effective business models for each regenerative medicine and cell therapy pipeline, guiding them from concept to commercialization.